Shephard Mpofu Selected Research

secukinumab

1/2021	Secukinumab provides sustained improvement in signs and symptoms and low radiographic progression in patients with psoriatic arthritis: 2-year (end-of-study) results from the FUTURE 5 study.
1/2021	Secukinumab Efficacy on Enthesitis in Patients With Ankylosing Spondylitis: Pooled Analysis of Four Pivotal Phase III Studies.
1/2020	Secukinumab provides sustained low rates of radiographic progression in psoriatic arthritis: 52-week results from a phase 3 study, FUTURE 5.
1/2020	Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial.
1/2020	Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Psoriatic Arthritis: Final 5-year Results from the Phase 3 FUTURE 1 Study.
12/2018	Correction to: Secukinumab Versus Adalimumab for Psoriatic Arthritis: Comparative Effectiveness up to 48 Weeks Using a Matching-Adjusted Indirect Comparison.
10/2018	Minimal Disease Activity Among Active Psoriatic Arthritis Patients Treated With Secukinumab: 2-Year Results From a Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase III Study.
6/2018	Secukinumab Versus Adalimumab for Psoriatic Arthritis: Comparative Effectiveness up to 48 Weeks Using a Matching-Adjusted Indirect Comparison.
1/2018	Secukinumab in the treatment of psoriatic arthritis: efficacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trial.
1/2018	Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3).

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Shephard Mpofu Research Topics

Disease

18	Psoriatic Arthritis 01/2021 - 08/2015
6	Infections 01/2020 - 06/2013
4	Psoriasis (Pustulosis Palmaris et Plantaris) 06/2018 - 08/2015
3	Ankylosing Spondylitis 01/2021 - 12/2015
3	Candidiasis (Moniliasis) 01/2020 - 12/2015
3	Crohn Disease (Crohn's Disease) 01/2020 - 12/2015
3	Rheumatoid Arthritis 03/2014 - 06/2013
2	Cardiovascular Diseases (Cardiovascular Disease) 01/2020 - 01/2018
2	Body Weight (Weight, Body) 06/2018 - 12/2015
2	Disease Progression 01/2018 - 01/2017
2	Chronic Disease (Chronic Diseases) 01/2017 - 03/2014
2	Fatigue 01/2017 - 03/2014
1	Colonic Neoplasms (Colon Cancer) 01/2020
1	Ulcerative Colitis 01/2018
1	Necrosis 01/2018
1	Pain (Aches) 01/2017
1	Neutropenia 12/2015
1	Stroke (Strokes) 10/2015
1	Myocardial Infarction 10/2015
1	Respiratory Tract Infections (Respiratory Tract Infection) 09/2015
1	Nasopharyngitis 09/2015

Drug/Important Bio-Agent (IBA)

24	secukinumabIBA 01/2021 - 06/2013
6	Interleukin-17 (Interleukin 17)IBA 01/2018 - 09/2015
3	Adalimumab (Humira)FDA Link 01/2020 - 06/2018
3	Monoclonal AntibodiesIBA 12/2015 - 08/2015
1	Methotrexate (Mexate)FDA LinkGeneric 06/2018
1	amsonic acid (DAS)IBA 11/2017
1	Tumor Necrosis Factor InhibitorsIBA 01/2016
1	CytokinesIBA 09/2015
1	Etanercept (Enbrel)FDA Link 08/2015
1	ametantrone (HAQ)IBA 03/2014

Therapy/Procedure

4	Therapeutics 06/2018 - 03/2014
1	Self Administration (Administration, Self) 01/2018